Method for the production and purification of adenoviral vectors

• US 6,194,191 B1
• Filed: 11/20/1997
• Issued: 02/27/2001
• Est. Priority Date: 11/20/1996
• Status: Expired due to Term

• Current Assignee: Crucell Holland B.V (Johnson & Johnson)
• Original Assignee: Introgen Therapeutics, Inc.
• Inventors: Thwin, Capucine, Cho, Toohyon, Zhang, Shuyuan, Wu, Zheng
• Primary Examiner(s): MOSHER, MARY
• Application Number:
  US08/975,519
• Time in Patent Office: 1,195 Days
• Field of Search: 435/235.1, 435/239, 435/320.1, 435/366, 435/369, 435/383, 424/199.1
• US Class Current: 435/239
• CPC Class Codes: A61K 35/761 Adenovirus
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4746 p53
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10045 Special targeting system for viral vectors
• CPC Class Codes: C12N 2710/10051 Methods of production or purification of viral material
• CPC Class Codes: C12N 2710/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/10351 Methods of production or purification of viral material
• CPC Class Codes: C12N 2810/6018 Adenoviridae
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

Claims

1. A method for producing a purified adenovirus composition comprising:

a) growing host cells in a media;

b) providing nutrients to said host cells by perfusion or through a fed-batch process;

c) infecting said host cells with an adenovirus;

d) lysing said host cells to provide a cell lysate comprising adenovirus, wherein said lysis is achieved through autolysis of infected cells; and

e) purifying adenovirus from said lysate to provide a purified adenovirus composition.

2. The method of claim 1, further comprising purifing adenovirus from said cell lysate by a process that comprises one or more chromatography steps.

3. The method of claim 2, wherein the chromatography step is a single chromatography step.

4. The method of claim 3, wherein said chromatography step is ion exchange chromatography.

5. The method of claim 4, wherein said ion exchange chromatography is anion exchange chromatography.

6. The method of claim 5, wherein said anion exchange chromatography utilizes DEAE, TMAE, QAE, or PEI.

7. The method of claim 5, wherein said anion exchange chromatography utilizes Toyopearl Super Q 650M, MonoQ, Source Q or Fractogel TMAE.

8. The method of claim 5, wherein said ion exchange chromatography is carried out at a pH range of between about 7.0 and about 10.0.

9. The method of claim 1, wherein the cells are perfused with a glucose containing media at a rate to provide a glucose concentration of between about 0.7 and 1.7 g/L.

10. The method of claim 1, wherein said exchanging buffer involves a diafiltration step.

11. The method of claim 1, wherein said adenovirus comprises an adenoviral vector encoding an exogenous gene construct.

12. The method of claim 11, wherein said gene construct is operatively linked to a promoter.

13. The method of claim 12, wherein said promoter is SV40 IE, RSV LTR, β

-actin, CMV IE, adenovirus major late, polyoma F9-1, or tyrosinase.

14. The method of claim 11, wherein said exogenous gene construct encodes a therapeutic gene.

15. The method of claim 14, wherein said therapeutic gene encodes antisense ras, antisense myc, antisense raf, antisense erb, antisense src, antisense fms, antisense jun, antisense trk, antisense ret, antisense gsp, antisense hst, antisense bcl antisense abl, Rb, CFTR, p16, p21, p27, p57, p73, C-CAM, APC, CTS-1, zac1, scFV ras, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, BRCA1, VHL, MMAC1, FCC, MCC, BRCA2, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 IL-12, GM-CSF G-CSF, thymidine kinase or p53.

16. The method of claim 15, wherein said therapeutic gene encodes p53.

17. The method of claim 1, wherein said adenovirus is a replication-incompetent adenovirus.

18. The method of claim 17, wherein the adenovirus is lacking at least a portion of the E1-region.

19. The method of claim 18, wherein the adenovirus is lacking at least a portion of the E1A and/or E1B region.

20. The method of claim 1, wherein said host cells are capable of complementing replication.

21. The method of claim 1, wherein said host cells are 293 cells.

22. The method of claim 1, wherein said cell lysate is treated with Benzonase®

, or Pulmozyme®

.

23. The method of claim 1, further comprising a concentration step employing membrane filtration.

24. The method of claim 23, wherein said filtration is tangential flow filtration.

25. The method of claim 23, wherein said filtration utilizes a 100 to 300K NMWC, regenerated cellulose, or polyether sulfone membrane.

26. The method of claim 1, wherein said media is a serum-free media and said host cells are capable of growing in serum-free media.

27. The method of claim 26, wherein said host cells have been adapted for growth in serum-free media by a sequential decrease in the fetal bovine serum content of the growth media.

28. The method of claim 1, wherein said cells are grown as a cell suspension culture.

29. The method of claim 1, wherein said cells are grown as an anchorage-dependent culture.

88. The method of claim 1, 30 or 86, wherein the nutrients are provided by a fed-batch process.

89. The method of claim 1, 30 or 86, wherein the nutrients are provided by perfusion.

30. A method for producing an adenovirus composition comprising:

a) growing host cells in a media comprising glucose;

b) providing nutrients to said cells by perfusion or a fed-batch process at a rate to provide a glucose concentration of less than 2.0 g/L;

c) infecting said host cells with an adenovirus; and

d) harvesting and lysing said host cells to produce a lysate comprising said adenovirus composition.

31. The method of claim 30, wherein the cells are provided nutrients at a rate to provide a glucose concentration of between about 0.7 and 1.7 g/L.

32. The method of claim 30, wherein said adenovirus comprises an adenoviral vector comprising an exogenous gene construct.

33. The method of claim 32, wherein said gene construct is operatively linked to a promoter.

34. The method of claim 33, wherein said promoter is SV40 IE, RSV LTR, β

-actin, CMV IE, adenovirus major late, polyoma F9-1, or tyrosinase.

35. The method of claim 32, wherein said exogenous gene construct encodes a therapeutic gene.

36. The method of claim 35, wherein said therapeutic gene encodes antisense ras, antisense myc, antisense raf, antisense erb, antisense src, antisense fms, antisense jun, antisense trk, antisense ret, antisense gsp, antisense hst, antisense bcl antisense abl, Rb, CFTR, p16, p21, p27, p57, p73, C-CAM, APC, CTS-1, zac1, scFV ras, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, BRCA1, VHL, MMAC1, FCC, MCC, BRCA2, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 IL-12, GM-CSF G-CSF, thymidine kinase or p53.

37. The method of claim 36, wherein said therapeutic gene encodes p53.

38. The method of claim 30, wherein said adenovirus is a replication-incompetent adenovirus.

39. The method of claim 38, wherein the adenovirus is lacking at least a portion of the E1-region.

40. The method of claim 39, wherein the adenovirus is lacking at least a portion of the E1A and/or E1B region.

41. The method of claim 30, wherein said host cells are capable of complementing replication.

42. The method of claim 30, wherein said host cells are 293 cells.

43. The method of claim 30, wherein said cells are harvested and lysed ex situ using a hypotonic solution, hypertonic solution, freeze-thaw, sonication, impinging jet, microfluidization or a detergent.

44. The method of claim 30, wherein said cells are harvested and lysed in situ using a hypotonic solution, hypertonic solution, or a detergent.

45. The method of claim 44, wherein said cells are lysed and harvested using detergent.

46. The method of claim 45, wherein said detergent is Thesit®

, NP-40®

, Tween-20®

, Brij-58®

, Triton X®

-100 or octyl glucoside.

47. The method of claim 30, further comprising purifying adenovirus from said cell lysate.

48. The method of claim 47, wherein said purifying involves treatment of the cell lysate with a nuclease.

49. The method of claim 48, wherein said nuclease is Benzonase®

or Pulmozyme®

.

50. The method of claim 47, wherein said purifying includes chromatography using one or more chromatography steps.

51. The method of claim 50, wherein said chromatography is a single chromatography step.

52. The method of claim 51, wherein said chromatography step involves ion exchange chromatography.

53. The method of claim 52, wherein said ion exchange chromatography is anion exchange chromatography.

54. The method of claim 53, wherein said anion exchange chromatography utilizes DEAE, TMAE, QAE, or PEI.

55. The method of claim 54, wherein said anion exchange chromatography utilizes Toyopearl Super Q 650M, MonoQ, Source Q or Fractogel TMAE.

56. The method of claim 55, wherein said ion exchange chromatography is carried out at a pH range of between about 7.0 and about 10.0.

57. The method of claim 30, wherein said media is subjected to diafiltration.

58. The method of claim 30, further comprising a concentration step employing membrane filtration.

59. The method of claim 58, wherein said filtration is tangential flow filtration.

60. The method of claim 58, wherein said filtration utilizes a 100 to 300K NMWC, regenerated cellulose, or polyether sulfone membrane.

61. A method for preparing a purified adenovirus composition comprising:

a) growing host cells;

b) providing nutrients to said host cells by perfusion or through a fed-batch process;

c) infecting said host cells with an adenovirus;

d) lysing said host cells using a process that includes hypotonic solution, hypertonic solution, impinging jet, microfluidization, solid shear, detergent, liquid shear, high pressure extrusion, autolysis or sonication to produce a crude lysate composition comprising adenovirus; and

e) purifying adenovirus from said lysate by a process that includes one or more chromatography steps without the use of cesium chloride density gradient centrifugation, to provide a purified adenovirus composition.

62. The method of claim 61, wherein the cells are lysed by solid shear, detergent lysis, liquid shear or sonication, to produce a cell lysate.

63. The method of claim 62, wherein the cells are lysed by detergent lysis.

64. The method of claim 63, wherein the cells are lysed by detergent Thesit®

, NP-40®

, Tween-20®

, Brij-58®

, Triton X-100®

or octyl glucoside.

65. The method of claim 64, wherein said detergent is present in the lysis solution at a concentration of about 1% (w/v).

66. The method of claim 61, wherein the cells are perfused in a glucose containing media at a rate to provide a glucose concentration of between about 0.7 and 1.7 g/L.

67. The method of claim 61, wherein said lysate is subjected to a diafiltration step.

68. The method of claim 61, wherein the chromatography is a single chromatography step.

69. The method of claim 68, wherein said chromatography step involves ion exchange chromatography.

70. The method of claim 61 wherein the lysing step d) uses hypotonic solution, hypertonic solution, impinging jet, microfluidization, solid shear, liquid shear, high pressure extrusion, or sonication.

71. A method for preparing a purified adenovirus composition comprising:

a) growing host cells in a serum-free media;

b) infecting said host cells with an adenovirus;

c) harvesting and lysing said host cells to provide a lysate comprising adenovirus; and

d) purifying adenovirus from said lysate by a process that includes a chromatography step without the use of cesium chloride density gradient centrifugation, wherein said chromatography step involves a single chromatography step, to provide a purified adenovirus composition wherein the recovery of purified adenovirus after the chromatography step is 70% ±

10% of the starting PFU.

72. The method of claim 71, wherein said chromatography step involves ion exchange chromatography.

73. The method of claim 72, wherein said ion exchange chromatography is anion exchange chromatography.

74. The method of claim 73, wherein said anion exchange chromatography utilizes DEAE, TMAE, QAE, or PEI.

75. The method of claim 73, wherein said anion exchange chromatography utilizes Toyopearl Super Q 650M, MonoQ, Source Q, or Fractogel TMAE.

76. The method of claim 71, wherein the adenovirus is subjected to purification steps that include reducing the concentration of contaminating nucleic acid.

77. The method of claim 71, further defined as comprising the steps of concentrating said cell lysate, exchanging buffer of said cell lysate, and reducing the concentration of contaminating nucleic acids in said cell lysate.

78. A method for preparing a purified adenovirus composition comprising:

a) growing host cells in a media;

b) infecting said host cells with an adenovirus;

c) harvesting and lysing said host cells to provide a lysate comprising adenovirus;

d) treating the lysate with a nuclease to reduce the concentration of contaminating nucleic acid; and

e) purifying adenovirus from said lysate by a process that includes a chromatography step without the use of cesium chloride density gradient centrifugation, wherein said chromatography step involves a single chromatography step, to provide a purified adenovirus composition wherein the recovery of purified adenovirus after the chromatography step is 70% ±

10% of the starting PFU.

79. The method of claim 78, wherein said chromatography step involves ion exchange chromatography.

80. The method of claim 79, wherein said ion exchange chromatography is anion exchange chromatography.

81. The method of claim 80, wherein said anion exchange chromatography utilizes DEAE, TMAE, QAE, or PEI.

82. The method of claim 80, wherein said anion exchange chromatography utilizes Toyopearl Super Q 650M, MonoQ, Source Q, or Fractogel TMAE.

83. The method of claim 78, wherein the adenovirus is subjected to purification steps that include reducing the concentration of contaminating nucleic acid.

84. The method of claim 78, further defined as comprising the steps of concentrating said cell lysate, and exchanging buffer of said cell lysate.

85. The method of claim 78, wherein said media is serum-free media and the cells are capable of growing in serum-free media.

86. A method for preparing a purified adenovirus composition comprising:

a) growing host cells;

b) providing nutrients to said host cells by perfusion or through a fed-batch process;

c) infecting said host cells with an adenovirus;

d) lysing said host cells using a process that includes hypotonic solution, hypertonic solution, impinging jet, microfluidization, solid shear, detergent, liquid shear, high pressure extrusion, autolysis or sonication to produce a crude lysate composition comprising adenovirus; and

e) purifying adenovirus from said lysate by a process that includes a chromatography step without the use of cesium chloride density gradient centrifugation, wherein said chromatography step involves a single chromatography step, to provide a purified adenovirus composition.

87. The method of claim 86 wherein the lysing step d) uses hypotonic solution, hypertonic solution, impinging jet, microfluidization, solid shear, liquid shear, high pressure extrusion, or sonication.